51 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;
commitment to expensive … additional safety studies prior to launch as a prerequisite of approval by regulatory authorities of such product;
commitment to expensive post
6-K
EX-99.2
OBSVF
ObsEva SA
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
and will fund all development and registration activities in China, starting with the commitment to conduct Phase 1 trials and a Phase 2 proof-of-concept trial
6-K
EX-99.1
OBSVF
ObsEva SA
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Theramex’s commitment is to listen
6-K
EX-99.1
OBSVF
ObsEva SA
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
brands covering contraception, fertility, menopause and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve
6-K
EX-99.2
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
, starting with the commitment to conduct Phase 1 trials and a Phase 2 proof-of-concept trial in China. We retain all rights to the product outside of China
6-K
EX-99.1
pzjeq15esbgqu 5f9
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
424B7
nxc ip65b2zwff8x0rv3
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
d2jcy690ezk
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
n40hgqm0rs1
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.3
eenn8mlxv7w
28 Jan 22
ObsEva Announces Corporate Updates
5:16pm
424B7
lhbytl1 e5
23 Nov 21
Prospectus with selling stockholder info
4:06pm
F-3
k1jdrdx2
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
3m6ii3veq106sxca09q
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K/A
EX-99.2
4w1gsa6c y7k8jr0gvr5
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
tkd2v8a
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
ohdkf57g31tyox5ss17
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
f5q0yvn35j6ryxal
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.2
juv77n
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am